Cloverfields Capital Group, LP Shattuck Labs, Inc. Transaction History

Cloverfields Capital Group, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Sep 07, 2023	BUY	$2.5 - $4.72 $112,500 - $212,400	45,000 New	45,000 $132,000
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.52 $851,528 - $1.81 Million	-327,511 Reduced 87.92%	45,000 $122,000
Q4 2021 Feb 14, 2022	BUY	$8.36 - $21.08 $2.74 Million - $6.9 Million	327,511 Added 727.8%	372,511 $3.17 Million
Q1 2021 May 13, 2021	BUY	$27.92 - $52.5 $1.26 Million - $2.36 Million	45,000 New	45,000 $1.32 Million

28.8M

300

1.2K

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $46.6M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

Get notified when there are updates to the investment portfolio of Cloverfields Capital Group, LP, based on Form 13F filings with the SEC.

Stay updated on Cloverfields Capital Group, LP with notifications on news.